Because the ubiquitination and subsequent degradation of IκBα in the proteasome are predominant mechanisms of the NF-κB pathway activation (Feng et al., 2017; Tundo et al., 2020), bortezomib, a reversible proteasome inhibitor, was used in the treatment of MM. This evidence concerns the gene NFKBIA and Miyoshi myopathy.